About one in five of those participating in the real-word study, published in the journal Diabetes, Obesity and Metabolism, perceived sweetness more intensely and a similar number were more sensitive to salt – and these changes were linked to a reduction in appetite.

“Incretin-based therapies such as Ozempic, Wegovy and Mounjaro are widely used for weight management but their effect on taste perception has been unclear,” says Othmar Moser, of University of Bayreuth, Bayreuth, Germany, who led the research.

“If changes in taste are linked to greater appetite control and weight loss, this could help clinicians better select therapies, provide more tailored dietary advice and improve long-term treatment outcomes for patients.”

To find out more, Professor Moser and colleagues from the Medical University of Vienna surveyed hundreds of individuals with overweight and obesity who were taking Ozempic, Wegovy or Mounjaro for weight loss about their sense of taste and appetite.

Of the 411 participants (69.6% female), 148 were on Ozempic, 217 were on Wegovy and 46 were taking Mounjaro.

Median duration of treatment was similar for the three groups (Ozempic: 43 weeks; Wegovy: 40 weeks; and Mounjaro: 47 weeks), with all of the participants receiving treatment for at least three consecutive months. The average BMI before starting treatment was 34.7 kg/m² (Ozempic), 35.6 kg/m² (Wegovy) and 36.2 kg/m² (Mounjaro).

The participants, who were recruited online, were asked if their sense of taste (perception of sweetness, saltiness, sourness and bitterness) had changed since starting treatment.

They were also asked about changes to appetite, satiety and food cravings, as well changes to lifestyle factors, such as smoking, and for self-reported data on height and weight before and during treatment.

Reductions in BMI, adjusted for duration of treatment, dose, baseline BMI, age and sex, were 17.4% with Ozempic, 17.6% with Wegovy and 15.5% with Mounjaro.

Around a fifth of the participants said that food tasted sweeter (21.3%) or saltier (22.6%) than before. Their perception of bitterness and sourness did not change.

Some 26.7% of participants in the Wegovy group reported that food tasted saltier than before, compared with 16.2% in the Ozempic group and 15.2% in the Mounjaro group. Increases in sweetness were reported at similar frequencies in all groups (Wegovy 19.4%, Ozempic 21.6%, Mounjaro 21.7%).

More than half of the participants (58.4%) reported they were less hungry in general, i.e. their appetite had decreased (Ozempic: 62.1%, Wegovy: 54.4%, Mounjaro: 56.5%).

Almost two-thirds of the participants (63.5%) reported increased satiety i.e. they felt full sooner Ozempic: 58.8%, Wegovy: 66.8%, Mounjaro: 63.1%). Food cravings were also reduced, with 41.3% of Mounjaro users reporting a strong reduction in cravings, i.e. their cravings were much less intense that before, compared with 34.1% of those taking Wegovy and 29.7% of those taking Ozempic.

Further analysis revealed links between changes to sense of taste and appetite and satiety.

Participants who reported that food tasted sweeter since starting incretin-based therapy were twice as likely to report increased satiety, compared with participants who said their perception of sweetness had not changed.

Those with an increase in the perception of sweetness were also 67% more likely to report a reduction in appetite and 85% more likely to report a reduction in cravings, compared with those whose perception of sweetness was unchanged.

Similarly, participants who said food tasted saltier than before were about twice as likely (2.17 times) to also reported increased satiety, compared with those whose perception of saltiness was unchanged.

Professor Moser says: “These drugs act not only in the gut and brain areas that control hunger but also on taste bud cells and brain regions that process taste and reward. This means they can subtly change how strong flavours, like sweetness or saltiness, are perceived. This, in turn, may affect appetite.”

However, there was no link between changes in taste perception and reduction in BMI. The researchers speculate this is because sense of taste is just one of many factors involved in weight loss.

Professor Moser explains: “Shifts in taste may affect how satisfying or appealing food feels in the moment, which influences appetite control. However, weight loss depends on many other factors – like metabolism, long-term eating patterns, and activity – so changes to taste alone may not be enough to directly drive body weight reduction.”

The study’s limitations include inability to prove causation, the self-reporting of data and the possibility that the participants weren’t representative of the patient group as a whole.

Professor Moser concludes: “Drugs like Wegovy, Ozempic and Mounjaro may alter sense of taste, making foods seem sweeter or saltier and helping people feel full sooner and less hungry. For clinical practice, this suggests that monitoring patients’ taste changes could provide useful clues about treatment response, even though taste alone does not directly drive weight loss.

“For example, tracking changes in taste could help gauge whether the treatment is working beyond weight loss.

“It could also perhaps be used to tailor dietary advice, for example by helping patients find alternatives to foods with flavours that have become overwhelming or less appealing.”

Food noise refers to obsessive and intrusive thoughts about food and eating. This preoccupation with food can hinder healthy lifestyle implementation and lead to overeating, making weight loss difficult.

Previous research has found that 57% of people who have living with overweight or obesity have experienced food noise, although few are familiar with the term. Many of those affected said that food noise made it more difficult to make healthy food choices or stick to an exercise plan.

Some people also report that food noise affects their quality of life and their well-being.

Glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (brand names Wegovy and Ozempic) are highly effective at helping people who are living with obesity lose weight. By mimicking the action of a hormone called GLP-1, they reduce appetite and feelings of hunger, slow the release of food from the stomach and increase feelings of fullness after eating.

However, little is known about how semaglutide, which was developed by Danish pharmaceutical company Novo Nordisk A/S, affects food noise.

To find out more, researchers from Novo Nordisk and Market Track LLC, a market research company, conducted a survey of 550 people in the US (average age 53 years, 86% female) who were taking semaglutide for weight loss.

Some 81% (447) of the participants said they had been taking semaglutide for at least four months and 86% of the participants reported weighing at least 92kg (14st 7lb) before starting treatment.

The participants were asked how food noise was currently affecting them and to recall how it had affected them before starting treatment.

Analysis of the results showed that the participants were experiencing less food noise than before.

The proportion of participants experiencing constant thoughts about food throughout the day fell almost four-fold from 62% before starting treatment to 16%. The proportion who said they spent too much time thinking about food fell by a similar amount, from 63% to 15%.

The proportion who said they had uncontrollable thoughts about food fell more than three-fold from 53% to 15%; the proportion who said their thoughts about food had negative effects on them or their life fell from 60% to 20%; and the proportion who said their thoughts about food distracted them from completing everyday activities fell from 47% to 15%.

The survey also contained questions that covered several areas of mental well-being.

Here, 352 (64%), 417 (76%) and 438 (80%) of the respondents reported an improvement in mental health, self-confidence and the development of healthier habits, respectively.

It is not known if these improvements were related to the drop in food noise or to the participants’ weight loss.

The study’s authors conclude that semaglutide may reduce the amount of food noise that is experienced by individuals who are living with obesity.

[Hebrew University of Jerusalem]- Dark matter, the elusive substance that makes up about 85% of the universe’s mass, remains one of the greatest mysteries in physics. Invisible and undetectable by ordinary means, it neither emits nor absorbs light, leaving scientists with only indirect evidence of its existence. For decades, researchers have tried in vain to catch a glimpse of these elusive particles.

Now, an international collaboration of scientists has unveiled promising first results with a novel experiment called QROCODILE (Quantum Resolution-Optimized Cryogenic Observatory for Dark matter Incident at Low Energy). The project, led jointly by the University of Zurich and the Hebrew University of Jerusalem, involving also Cornell University, Karlsruhe Institute of Technology (KIT), and MIT, has demonstrated a new path in the search for “light” dark matter particles.

At the heart of QROCODILE is a cutting-edge superconducting detector capable of measuring incredibly faint energy deposits — down to just 0.11 electron-volts, millions of times smaller than the energies usually detected in particle physics experiments. This sensitivity opens an entirely new frontier: testing the existence of extremely light dark matter particles, with masses thousands of times smaller than those probed by previous experiments.

In a science run lasting more than 400 hours at temperatures near absolute zero, the team recorded a small number of unexplained signals. While these events cannot yet be confirmed as dark matter — they may stem from cosmic rays or natural background radiation — they already allow researchers to set new world-leading limits on how light dark matter particles interact with electrons and atomic nuclei

An additional strength of the experiment is its potential to detect the directionality of incoming signals. Since the Earth moves through the galactic halo, dark matter particles are expected to arrive from a preferred direction. Future upgrades could allow scientists to distinguish between true dark matter signals and random background noise, a crucial step toward a definitive discovery.

Prof. Yonit Hochberg of the Racah Institute of Physics at the Hebrew University, one of the project’s lead scientists, explains: “For the first time, we’ve placed new constraints on the existence of especially light dark matter. This is an important first step toward larger experiments that could ultimately achieve the long-sought direct detection.”

The next stage of the project, NILE QROCODILE, will further enhance the detector’s sensitivity and move the experiment underground to shield it from cosmic rays. With improved shielding, larger detector arrays, and even lower energy thresholds, the researchers aim to push the boundaries of our understanding of the dark universe.